Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.77 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.76 |
| ▸ | JAK3 | P52333 | 2/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.70 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478966 | 1.00 | EGFR (1.00) | EGFRERBB3DUS2ERBB2KDR | |
| SCHEMBL21801932 | 1.00 | EGFR (1.00) | EGFRERBB3DUS2ERBB2KDR | |
| SCHEMBL19480001 | 0.91 | EGFR (0.83) | EGFRERBB3DUS2ERBB2KDR | |
| SCHEMBL29731552 | 0.90 | EGFR (0.82) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL22847994 | 0.90 | EGFR (0.82) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL30474633 | 0.89 | EGFR (0.81) | EGFRERBB3DUS2ERBB2KDR | |
| SCHEMBL19185507 | 0.89 | EGFR (0.81) | EGFRERBB3DUS2ERBB2KDR | |
| SCHEMBL25649216 | 0.88 | EGFR (0.78) | EGFRERBB3DUS2ERBB2KDR | |
| SCHEMBL25829 | 0.88 | EGFR (0.80) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL18862642 | 0.88 | EGFR (0.80) | EGFRERBB3DUS2ERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146049-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-05-28 | — | — | US | disclosed |
| US-20260146050-A1 | KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-05-28 | — | — | US | disclosed |
| EP-4719603-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-12545670-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-02-10 | — | — | US | disclosed |
| EP-4157836-B1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250313553-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTL GMBH CORP (DE) | 2025-10-09 | — | — | US | disclosed |
| US-20250296940-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTL GMBH CORP (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4608820-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Boehringer Ingelheim International GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608819-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Boehringer Ingelheim International GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608818-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Boehringer Ingelheim International GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| WO-2023099624-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023099623-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023099608-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| CN-116234806-A | Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116034106-A | Cyclic 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-4157836-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157837-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| US-20220388986-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-12-08 | — | — | US | disclosed |
| US-20220133734-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| WO-2022090481-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388986-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | STING1, IRF3, CGAS | EGFR 3145/4885ERBB3 4176/4885DUS2 2578/4885 |
| US-12545670-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | KRAS, HRAS, NRAS | EGFR 49/4885ERBB3 47/4885DUS2 2923/4885 |
| US-20250313553-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | EGFR 85/4885ERBB3 99/4885DUS2 985/4885 |
| US-20260146050-A1 | KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES | KRAS, NRAS, HRAS | EGFR 15/4885ERBB3 45/4885DUS2 3049/4885 |
| US-20220133734-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB4, ERBB2 | EGFR 1/4885ERBB3 4/4885DUS2 2873/4885 |
| US-20250296940-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, RSU1, NRAS | EGFR 213/4885ERBB3 164/4885DUS2 1212/4885 |
| US-20260146049-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | EGFR 146/4885ERBB3 86/4885DUS2 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.